Date: March 08, 2012
Alameda, California — Abbott (NYSE: ABT) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System,[i] the first from Abbott to include a touch-screen interface, automated logbook and several personalization features designed to improve the diabetes management experience for patients. This unique device is also equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their health care providers. The FreeStyle InsuLinx System will be available to U.S. consumers within the coming months.
According to the American Diabetes Association (ADA), approximately 25.8 million people in the United States have diabetes,[ii] and of those, many require insulin to manage their condition. The FreeStyle InsuLinx System is the newest addition to Abbott’s portfolio of glucose monitoring systems and is designed to use FreeStyle technology to help insulin-using patients monitor their blood glucose levels to allow them to more effectively manage their condition. Specifically, the FreeStyle InsuLinx System offers:
The new FreeStyle InsuLinx blood glucose monitor includes an automated logbook, easy-to-use touch screen and personalization features.
The FreeStyle InsuLinx System is compatible with the FreeStyle InsuLinx blood glucose test strips.
"The new FreeStyle InsuLinx System represents Abbott’s latest advancement in delivering innovative products for people with diabetes who use insulin," said Heather L. Mason, senior vice president, Abbott Diabetes Care. "The improved functionality, data sharing tools and personalization features are designed to improve the diabetes management experience for patients. We are excited to make this product available to diabetes patients in the United States."
Abbott Diabetes Care, based in Alameda, California, is a leader in developing, manufacturing and marketing glucose monitoring systems designed to help people better manage their diabetes. Additional information about Abbott Diabetes Care may be found at www.abbottdiabetescare.com.
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionally, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.
[i] FreeStyle and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions.
[ii] American Diabetes Association: http://www.diabetes.org/diabetes-basics/diabetes-statistics/
Boston, MA—In a new study, researchers from the Harvard School of Public Health (HSPH) have found that eating processed meat, such as bacon, sausage or processed deli meats, was associated with a 42% higher risk of heart disease and a 19% higher risk of type 2 diabetes. In contrast, the researchers did not find any higher risk of heart disease or diabetes among individuals eating unprocessed red meat, such as from beef, pork, or lamb. This work is the first systematic review and meta-analysis of the worldwide evidence for how eating unprocessed red meat and processed meat relates to risk of cardiovascular diseases and diabetes.
A DIABETIC woman from Northampton has been presented with a medal to mark 70 years of coping with the condition.
When Grace Jarnell was diagnosed with Type 1 diabetes while aged 12 in 1942, treatment was so basic she had to heat her own samples at home over a Bunsen burner to see if she needed insulin.
Now, more than 100,000 injections later, she has defied the worst fears of doctors and been awarded a medal in recognition of seven decades of coping with the condition.